FDA Announces Intent to Take Action Against Non-FDA-Approved GLP-1 Drugs

On February 6, 2026, the FDA announced its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs mass-marketed as alternatives to FDA-approved drugs. The agency named Hims & Hers and other compounding pharmacies in the announcement.

The FDA also said it would combat misleading direct-to-consumer advertising for these products. The agency warned that violations could lead to legal action, including seizure and injunction.

Precision about the legal status of this announcement is essential. February 6, 2026, was a statement of intent, not a final rule, a ban, or a court order, and no product was banned by this announcement itself. It described enforcement steps the agency intended to take.

The announcement fits the distinction the FDA draws across the GLP-1 category: FDA approval belongs to a specific approved drug product and its labeled indication, while compounded products are not FDA-approved and are regulated under separate rules. That distinction, not any single company name, is the regulatory point of the February 6 statement.